| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 43 | 2020 | 77 | 16.110 |
Why?
|
| Surgical Flaps | 66 | 2020 | 241 | 12.670 |
Why?
|
| Mammaplasty | 38 | 2019 | 107 | 9.930 |
Why?
|
| Lymphatic Vessels | 22 | 2020 | 68 | 7.610 |
Why?
|
| Lymph Nodes | 21 | 2020 | 533 | 6.290 |
Why?
|
| Free Tissue Flaps | 18 | 2017 | 49 | 6.120 |
Why?
|
| Postoperative Complications | 40 | 2019 | 2207 | 3.590 |
Why?
|
| Breast Neoplasms | 33 | 2019 | 2903 | 3.410 |
Why?
|
| Microsurgery | 13 | 2020 | 84 | 3.250 |
Why?
|
| Mastectomy | 16 | 2019 | 243 | 2.710 |
Why?
|
| Tissue and Organ Harvesting | 7 | 2019 | 78 | 2.390 |
Why?
|
| Sarcoma | 13 | 2012 | 215 | 2.310 |
Why?
|
| Lymphography | 12 | 2018 | 27 | 2.230 |
Why?
|
| Veins | 6 | 2018 | 94 | 2.230 |
Why?
|
| Bone Neoplasms | 8 | 2012 | 322 | 2.020 |
Why?
|
| Anastomosis, Surgical | 7 | 2018 | 267 | 1.590 |
Why?
|
| Fibula | 6 | 2012 | 32 | 1.490 |
Why?
|
| Indocyanine Green | 5 | 2018 | 22 | 1.480 |
Why?
|
| Humans | 143 | 2020 | 86643 | 1.470 |
Why?
|
| Rectus Abdominis | 9 | 2013 | 37 | 1.370 |
Why?
|
| Female | 97 | 2020 | 44532 | 1.370 |
Why?
|
| Osteosarcoma | 7 | 2012 | 158 | 1.360 |
Why?
|
| Perforator Flap | 4 | 2016 | 12 | 1.260 |
Why?
|
| Middle Aged | 66 | 2020 | 25028 | 1.240 |
Why?
|
| Lymph Node Excision | 5 | 2019 | 217 | 1.140 |
Why?
|
| Breast Implants | 4 | 2011 | 23 | 1.110 |
Why?
|
| Retrospective Studies | 40 | 2020 | 8489 | 1.040 |
Why?
|
| Extremities | 3 | 2018 | 167 | 1.040 |
Why?
|
| Lymphatic System | 7 | 2020 | 53 | 1.030 |
Why?
|
| Hernia, Abdominal | 2 | 2015 | 14 | 0.990 |
Why?
|
| Adult | 56 | 2020 | 25648 | 0.990 |
Why?
|
| Follow-Up Studies | 20 | 2016 | 3640 | 0.950 |
Why?
|
| Quality of Life | 6 | 2020 | 1585 | 0.950 |
Why?
|
| Hemipelvectomy | 5 | 2015 | 5 | 0.940 |
Why?
|
| Bone Transplantation | 7 | 2012 | 64 | 0.940 |
Why?
|
| Salvage Therapy | 3 | 2016 | 233 | 0.920 |
Why?
|
| Soft Tissue Neoplasms | 6 | 2012 | 127 | 0.910 |
Why?
|
| Mammary Arteries | 4 | 2013 | 31 | 0.890 |
Why?
|
| Wound Healing | 9 | 2019 | 344 | 0.880 |
Why?
|
| Aged | 44 | 2020 | 18415 | 0.880 |
Why?
|
| Treatment Outcome | 29 | 2016 | 7993 | 0.870 |
Why?
|
| Spinal Neoplasms | 4 | 2010 | 50 | 0.860 |
Why?
|
| Skull Base Neoplasms | 5 | 2011 | 11 | 0.850 |
Why?
|
| Arm | 5 | 2012 | 91 | 0.830 |
Why?
|
| Vascularized Composite Allotransplantation | 2 | 2019 | 13 | 0.830 |
Why?
|
| Cutaneous Fistula | 2 | 2016 | 11 | 0.810 |
Why?
|
| Epigastric Arteries | 4 | 2016 | 9 | 0.790 |
Why?
|
| Lymphoscintigraphy | 2 | 2018 | 4 | 0.760 |
Why?
|
| Myocutaneous Flap | 2 | 2017 | 5 | 0.720 |
Why?
|
| Chyle | 1 | 2019 | 5 | 0.700 |
Why?
|
| Reoperation | 11 | 2015 | 597 | 0.690 |
Why?
|
| Vascular Surgical Procedures | 4 | 2007 | 148 | 0.690 |
Why?
|
| Thoracic Wall | 2 | 2010 | 21 | 0.670 |
Why?
|
| Skin Transplantation | 6 | 2020 | 172 | 0.650 |
Why?
|
| Optical Imaging | 1 | 2018 | 48 | 0.650 |
Why?
|
| Leg | 4 | 2013 | 137 | 0.640 |
Why?
|
| Skull Base | 4 | 2011 | 47 | 0.630 |
Why?
|
| Radiation Injuries | 3 | 2017 | 155 | 0.610 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 131 | 0.600 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2017 | 15 | 0.600 |
Why?
|
| Superficial Back Muscles | 1 | 2016 | 1 | 0.600 |
Why?
|
| Thrombosis | 3 | 2018 | 296 | 0.590 |
Why?
|
| Male | 42 | 2020 | 40965 | 0.590 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 80 | 0.590 |
Why?
|
| Respiratory Tract Fistula | 1 | 2016 | 9 | 0.590 |
Why?
|
| Radiation Exposure | 1 | 2017 | 24 | 0.590 |
Why?
|
| Pharynx | 1 | 2016 | 45 | 0.580 |
Why?
|
| Surgery, Plastic | 1 | 2017 | 42 | 0.580 |
Why?
|
| Larynx | 1 | 2016 | 38 | 0.570 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 220 | 0.570 |
Why?
|
| Laryngeal Neoplasms | 1 | 2017 | 89 | 0.570 |
Why?
|
| Graft Survival | 10 | 2017 | 884 | 0.560 |
Why?
|
| Pelvic Neoplasms | 2 | 2015 | 45 | 0.550 |
Why?
|
| Adolescent | 18 | 2020 | 8981 | 0.550 |
Why?
|
| Combined Modality Therapy | 9 | 2016 | 1686 | 0.540 |
Why?
|
| Lower Extremity | 4 | 2020 | 84 | 0.540 |
Why?
|
| Sural Nerve | 3 | 2008 | 19 | 0.530 |
Why?
|
| Logistic Models | 8 | 2016 | 1186 | 0.520 |
Why?
|
| Periosteum | 3 | 2009 | 10 | 0.510 |
Why?
|
| Muscle, Skeletal | 5 | 2011 | 449 | 0.500 |
Why?
|
| Breast | 4 | 2013 | 288 | 0.500 |
Why?
|
| Postoperative Care | 1 | 2016 | 221 | 0.500 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 157 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2017 | 1076 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2010 | 1313 | 0.480 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2012 | 68 | 0.480 |
Why?
|
| Child | 14 | 2020 | 6927 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 2 | 2010 | 252 | 0.480 |
Why?
|
| Ribs | 3 | 2009 | 45 | 0.480 |
Why?
|
| Sacrum | 2 | 2012 | 40 | 0.470 |
Why?
|
| Enzyme Precursors | 2 | 2003 | 20 | 0.460 |
Why?
|
| Limb Salvage | 4 | 2015 | 33 | 0.460 |
Why?
|
| Melanoma | 2 | 2016 | 459 | 0.440 |
Why?
|
| Bone and Bones | 3 | 2009 | 265 | 0.440 |
Why?
|
| Caspases | 2 | 2003 | 155 | 0.440 |
Why?
|
| Prospective Studies | 7 | 2017 | 4213 | 0.440 |
Why?
|
| Rabbits | 2 | 2013 | 636 | 0.430 |
Why?
|
| Mandibular Neoplasms | 2 | 2009 | 24 | 0.430 |
Why?
|
| Surgeons | 1 | 2017 | 238 | 0.430 |
Why?
|
| Coloring Agents | 4 | 2013 | 64 | 0.430 |
Why?
|
| Young Adult | 12 | 2020 | 5976 | 0.430 |
Why?
|
| Forelimb | 1 | 2012 | 17 | 0.420 |
Why?
|
| Facial Nerve | 2 | 2011 | 33 | 0.420 |
Why?
|
| Genital Neoplasms, Female | 1 | 2013 | 107 | 0.410 |
Why?
|
| Upper Extremity | 3 | 2020 | 52 | 0.410 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 6509 | 0.400 |
Why?
|
| Leg Bones | 1 | 2011 | 7 | 0.400 |
Why?
|
| Cosmetic Techniques | 1 | 2011 | 28 | 0.400 |
Why?
|
| Urethra | 1 | 2012 | 113 | 0.400 |
Why?
|
| Abdomen | 3 | 2008 | 122 | 0.390 |
Why?
|
| Tissue Transplantation | 2 | 2000 | 12 | 0.390 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 292 | 0.370 |
Why?
|
| Pharyngeal Diseases | 2 | 2016 | 11 | 0.360 |
Why?
|
| Foot Diseases | 3 | 2011 | 12 | 0.350 |
Why?
|
| Spine | 1 | 2010 | 102 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 5 | 2011 | 1052 | 0.340 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.340 |
Why?
|
| Thoracotomy | 1 | 2009 | 58 | 0.340 |
Why?
|
| Skin | 5 | 2017 | 554 | 0.330 |
Why?
|
| Femur | 2 | 2012 | 116 | 0.330 |
Why?
|
| Risk Factors | 9 | 2016 | 5417 | 0.330 |
Why?
|
| Stents | 2 | 2016 | 377 | 0.320 |
Why?
|
| Cicatrix | 2 | 2005 | 63 | 0.310 |
Why?
|
| Symptom Assessment | 2 | 2018 | 65 | 0.310 |
Why?
|
| Transplantation, Autologous | 3 | 2015 | 331 | 0.310 |
Why?
|
| Esthetics | 4 | 2010 | 44 | 0.310 |
Why?
|
| Mouth Neoplasms | 1 | 2009 | 194 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 3 | 2012 | 318 | 0.300 |
Why?
|
| Pectoralis Muscles | 3 | 2007 | 7 | 0.300 |
Why?
|
| Mandible | 1 | 2008 | 119 | 0.290 |
Why?
|
| Angiography | 2 | 2018 | 208 | 0.290 |
Why?
|
| Erectile Dysfunction | 2 | 2008 | 74 | 0.290 |
Why?
|
| Pelvic Bones | 3 | 2012 | 44 | 0.280 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2006 | 44 | 0.280 |
Why?
|
| Child, Preschool | 6 | 2020 | 3612 | 0.280 |
Why?
|
| Ofloxacin | 1 | 2005 | 5 | 0.280 |
Why?
|
| Drainage | 2 | 2017 | 157 | 0.280 |
Why?
|
| Amputation, Traumatic | 1 | 2005 | 9 | 0.280 |
Why?
|
| Finger Injuries | 1 | 2005 | 11 | 0.280 |
Why?
|
| Axilla | 3 | 2019 | 99 | 0.270 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2005 | 40 | 0.270 |
Why?
|
| Lumbar Vertebrae | 2 | 2012 | 148 | 0.270 |
Why?
|
| Replantation | 1 | 2005 | 36 | 0.270 |
Why?
|
| Clavicle | 2 | 2017 | 11 | 0.260 |
Why?
|
| Transplantation, Homologous | 4 | 2011 | 996 | 0.260 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2001 | 5 | 0.260 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2004 | 25 | 0.250 |
Why?
|
| Dogs | 4 | 2013 | 685 | 0.250 |
Why?
|
| Time Factors | 11 | 2015 | 5210 | 0.240 |
Why?
|
| Animals | 17 | 2016 | 26582 | 0.240 |
Why?
|
| Inflammation | 2 | 2015 | 920 | 0.240 |
Why?
|
| Penis | 2 | 2008 | 57 | 0.240 |
Why?
|
| Prostatectomy | 2 | 2008 | 471 | 0.240 |
Why?
|
| Body Mass Index | 4 | 2012 | 770 | 0.240 |
Why?
|
| Incidence | 4 | 2013 | 1577 | 0.240 |
Why?
|
| Angioplasty, Balloon | 1 | 2004 | 95 | 0.240 |
Why?
|
| Neoplasms | 3 | 2015 | 2898 | 0.230 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 486 | 0.230 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2003 | 5 | 0.230 |
Why?
|
| Maxilla | 1 | 2003 | 19 | 0.230 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 112 | 0.220 |
Why?
|
| Radiography | 3 | 2012 | 813 | 0.220 |
Why?
|
| Pharyngectomy | 1 | 2002 | 8 | 0.220 |
Why?
|
| Laryngectomy | 1 | 2002 | 26 | 0.210 |
Why?
|
| Jejunum | 1 | 2002 | 79 | 0.210 |
Why?
|
| Mandibular Diseases | 1 | 2001 | 16 | 0.210 |
Why?
|
| Fistula | 1 | 2002 | 42 | 0.210 |
Why?
|
| Osteoradionecrosis | 1 | 2001 | 18 | 0.210 |
Why?
|
| Thoracic Arteries | 1 | 2001 | 6 | 0.210 |
Why?
|
| Smoking | 2 | 2009 | 609 | 0.200 |
Why?
|
| Lipectomy | 2 | 2016 | 9 | 0.200 |
Why?
|
| Cryotherapy | 3 | 2006 | 29 | 0.200 |
Why?
|
| Tacrolimus | 1 | 2003 | 373 | 0.200 |
Why?
|
| Lymphangiogenesis | 3 | 2016 | 38 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2015 | 2261 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2015 | 1939 | 0.190 |
Why?
|
| Pilonidal Sinus | 1 | 2000 | 3 | 0.190 |
Why?
|
| Low-Level Light Therapy | 3 | 2005 | 15 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 746 | 0.190 |
Why?
|
| Chondrosarcoma | 2 | 2012 | 48 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2015 | 1538 | 0.180 |
Why?
|
| Microcirculation | 3 | 2013 | 106 | 0.180 |
Why?
|
| Trauma Centers | 1 | 2020 | 116 | 0.180 |
Why?
|
| Osteogenesis | 4 | 2009 | 242 | 0.180 |
Why?
|
| Surgical Mesh | 2 | 2013 | 116 | 0.180 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 28 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2001 | 184 | 0.180 |
Why?
|
| Transplant Donor Site | 1 | 2019 | 3 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2009 | 1204 | 0.170 |
Why?
|
| Composite Tissue Allografts | 1 | 2019 | 7 | 0.170 |
Why?
|
| Africa | 1 | 2019 | 98 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2019 | 86 | 0.170 |
Why?
|
| Recovery of Function | 2 | 2012 | 272 | 0.170 |
Why?
|
| Guided Tissue Regeneration | 2 | 2009 | 7 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 150 | 0.170 |
Why?
|
| Omentum | 2 | 2010 | 71 | 0.160 |
Why?
|
| Europe | 1 | 2019 | 309 | 0.160 |
Why?
|
| Regional Blood Flow | 3 | 2005 | 197 | 0.160 |
Why?
|
| Graft Rejection | 3 | 2015 | 1065 | 0.160 |
Why?
|
| Organ Size | 1 | 2018 | 364 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 272 | 0.160 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 231 | 0.150 |
Why?
|
| Tissue Engineering | 2 | 2013 | 181 | 0.150 |
Why?
|
| Pyridines | 1 | 2019 | 310 | 0.150 |
Why?
|
| Proteins | 1 | 2003 | 777 | 0.150 |
Why?
|
| Apoptosis | 2 | 2005 | 1683 | 0.150 |
Why?
|
| Groin | 1 | 2017 | 8 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
| Abdominal Fat | 1 | 2017 | 13 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 185 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2017 | 16 | 0.150 |
Why?
|
| Esophageal Stenosis | 1 | 2017 | 26 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2017 | 126 | 0.150 |
Why?
|
| Radiation Protection | 1 | 2017 | 25 | 0.150 |
Why?
|
| Diphtheria Toxin | 1 | 2016 | 20 | 0.150 |
Why?
|
| Forearm | 1 | 2016 | 32 | 0.150 |
Why?
|
| Compression Bandages | 1 | 2016 | 7 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1056 | 0.140 |
Why?
|
| Health Information Exchange | 1 | 2016 | 12 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 468 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2015 | 2767 | 0.140 |
Why?
|
| Sheep | 4 | 2009 | 239 | 0.140 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 171 | 0.140 |
Why?
|
| Microinjections | 2 | 2013 | 70 | 0.140 |
Why?
|
| Prognosis | 4 | 2015 | 3679 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2016 | 80 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2017 | 80 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 175 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2015 | 596 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 268 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1801 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2016 | 103 | 0.130 |
Why?
|
| Algorithms | 4 | 2015 | 1830 | 0.130 |
Why?
|
| Epidermis | 3 | 2005 | 100 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 312 | 0.130 |
Why?
|
| Administration, Topical | 2 | 2005 | 95 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Blood Vessels | 2 | 2005 | 94 | 0.130 |
Why?
|
| Vascular Grafting | 1 | 2014 | 15 | 0.130 |
Why?
|
| Body Image | 1 | 2015 | 76 | 0.130 |
Why?
|
| Nipples | 1 | 2014 | 37 | 0.120 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 38 | 0.120 |
Why?
|
| Thrombectomy | 1 | 2016 | 158 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2601 | 0.120 |
Why?
|
| Radiotherapy Dosage | 2 | 2008 | 468 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2013 | 2 | 0.120 |
Why?
|
| Fasciotomy | 1 | 2013 | 16 | 0.120 |
Why?
|
| Infant | 3 | 2020 | 3046 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 930 | 0.120 |
Why?
|
| Recurrence | 2 | 2010 | 1139 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2016 | 428 | 0.120 |
Why?
|
| Burns | 2 | 2006 | 131 | 0.120 |
Why?
|
| Brachiocephalic Veins | 1 | 2013 | 33 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 160 | 0.120 |
Why?
|
| Morbidity | 1 | 2013 | 148 | 0.120 |
Why?
|
| Prevalence | 1 | 2017 | 1239 | 0.110 |
Why?
|
| Caspase 9 | 2 | 2003 | 48 | 0.110 |
Why?
|
| Obesity | 1 | 2000 | 963 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 546 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 912 | 0.110 |
Why?
|
| Cryosurgery | 2 | 2003 | 41 | 0.110 |
Why?
|
| Dimerization | 2 | 2003 | 143 | 0.110 |
Why?
|
| Microvessels | 2 | 2012 | 70 | 0.110 |
Why?
|
| Cadaver | 1 | 2013 | 185 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2016 | 408 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2013 | 303 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1673 | 0.110 |
Why?
|
| Thigh | 1 | 2012 | 38 | 0.110 |
Why?
|
| Implants, Experimental | 3 | 2009 | 16 | 0.110 |
Why?
|
| Pain | 1 | 2015 | 391 | 0.110 |
Why?
|
| Torso | 1 | 2012 | 12 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 685 | 0.100 |
Why?
|
| Sarcoma, Ewing | 1 | 2012 | 42 | 0.100 |
Why?
|
| Fascia | 2 | 2013 | 30 | 0.100 |
Why?
|
| Facial Muscles | 1 | 2011 | 23 | 0.100 |
Why?
|
| HeLa Cells | 2 | 2003 | 498 | 0.100 |
Why?
|
| Forehead | 1 | 2011 | 15 | 0.100 |
Why?
|
| Macrophages | 1 | 2015 | 554 | 0.100 |
Why?
|
| Neurofibromatosis 1 | 1 | 2011 | 36 | 0.100 |
Why?
|
| Lasers | 3 | 2006 | 106 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2003 | 692 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 232 | 0.100 |
Why?
|
| Depression | 1 | 2015 | 473 | 0.100 |
Why?
|
| Cellulitis | 1 | 2010 | 19 | 0.100 |
Why?
|
| Vagina | 1 | 2012 | 161 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 2232 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 243 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2705 | 0.090 |
Why?
|
| Electric Stimulation | 1 | 2011 | 347 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2010 | 5 | 0.090 |
Why?
|
| Contraindications | 1 | 2010 | 72 | 0.090 |
Why?
|
| Oral Fistula | 1 | 2009 | 2 | 0.090 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 10 | 0.090 |
Why?
|
| Necrosis | 2 | 2000 | 204 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2009 | 50 | 0.090 |
Why?
|
| Tracheostomy | 1 | 2009 | 42 | 0.090 |
Why?
|
| Penile Erection | 1 | 2008 | 22 | 0.080 |
Why?
|
| Germany | 1 | 2008 | 72 | 0.080 |
Why?
|
| Dental Occlusion | 1 | 2008 | 5 | 0.080 |
Why?
|
| Skin Temperature | 2 | 2006 | 14 | 0.080 |
Why?
|
| Bone Plates | 1 | 2008 | 23 | 0.080 |
Why?
|
| Prosthesis Failure | 1 | 2008 | 111 | 0.080 |
Why?
|
| Antibody Specificity | 1 | 2008 | 129 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2008 | 117 | 0.080 |
Why?
|
| Chordoma | 1 | 2007 | 19 | 0.080 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2004 | 6 | 0.080 |
Why?
|
| Dog Diseases | 1 | 2007 | 35 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2008 | 120 | 0.080 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 14 | 0.070 |
Why?
|
| Thoracic Neoplasms | 1 | 2006 | 64 | 0.070 |
Why?
|
| Device Removal | 1 | 2008 | 161 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1578 | 0.070 |
Why?
|
| Histiocytoma | 1 | 2005 | 1 | 0.070 |
Why?
|
| Bony Callus | 1 | 2005 | 5 | 0.070 |
Why?
|
| Ointments | 1 | 2005 | 12 | 0.070 |
Why?
|
| Diaphyses | 1 | 2005 | 6 | 0.070 |
Why?
|
| Ophthalmic Solutions | 1 | 2005 | 16 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1863 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 943 | 0.070 |
Why?
|
| Foot | 1 | 2005 | 50 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2007 | 207 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2004 | 157 | 0.060 |
Why?
|
| Chlorofluorocarbons | 1 | 2004 | 1 | 0.060 |
Why?
|
| Absorbable Implants | 1 | 2005 | 34 | 0.060 |
Why?
|
| Aerosols | 1 | 2004 | 44 | 0.060 |
Why?
|
| Carotid Artery, External | 1 | 2004 | 8 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 999 | 0.060 |
Why?
|
| Balloon Occlusion | 1 | 2004 | 27 | 0.060 |
Why?
|
| Cell Movement | 1 | 2008 | 758 | 0.060 |
Why?
|
| Jugular Veins | 1 | 2004 | 69 | 0.060 |
Why?
|
| Fibrosis | 2 | 2015 | 203 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 916 | 0.060 |
Why?
|
| Intracranial Embolism | 1 | 2004 | 29 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 263 | 0.060 |
Why?
|
| Pain, Postoperative | 2 | 2008 | 240 | 0.060 |
Why?
|
| Skin Diseases, Vascular | 1 | 2003 | 3 | 0.060 |
Why?
|
| Carcinoma | 2 | 2007 | 436 | 0.060 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2003 | 7 | 0.060 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2003 | 8 | 0.060 |
Why?
|
| Caspase 10 | 1 | 2003 | 5 | 0.060 |
Why?
|
| Caspase 2 | 1 | 2003 | 9 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2003 | 34 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 116 | 0.060 |
Why?
|
| Morphine | 2 | 2001 | 130 | 0.060 |
Why?
|
| Tourniquets | 1 | 2002 | 7 | 0.060 |
Why?
|
| Laser Coagulation | 1 | 2003 | 54 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2003 | 393 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 206 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 113 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 806 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 214 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1376 | 0.050 |
Why?
|
| Swine | 2 | 2013 | 555 | 0.050 |
Why?
|
| Ketorolac | 1 | 2001 | 6 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 439 | 0.050 |
Why?
|
| Texas | 1 | 2001 | 101 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 1041 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 896 | 0.050 |
Why?
|
| Biopsy | 2 | 2015 | 1163 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.050 |
Why?
|
| Hypertension | 1 | 2009 | 1141 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2001 | 46 | 0.050 |
Why?
|
| Dura Mater | 1 | 2000 | 44 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2001 | 105 | 0.050 |
Why?
|
| Nerve Regeneration | 2 | 2011 | 32 | 0.050 |
Why?
|
| Hematoma | 1 | 2001 | 104 | 0.050 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2020 | 156 | 0.050 |
Why?
|
| Emergencies | 1 | 2020 | 113 | 0.050 |
Why?
|
| Skull | 1 | 2001 | 249 | 0.040 |
Why?
|
| Oropharynx | 1 | 1999 | 15 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 455 | 0.040 |
Why?
|
| Mouth | 1 | 1999 | 48 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3092 | 0.040 |
Why?
|
| Deglutition | 1 | 1999 | 73 | 0.040 |
Why?
|
| Health Policy | 1 | 2020 | 180 | 0.040 |
Why?
|
| Speech | 1 | 1999 | 84 | 0.040 |
Why?
|
| Risk | 1 | 2000 | 674 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 552 | 0.040 |
Why?
|
| Cell Line | 1 | 2003 | 2468 | 0.040 |
Why?
|
| Age Factors | 1 | 2003 | 1851 | 0.040 |
Why?
|
| Diffusion Chambers, Culture | 2 | 2009 | 6 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2000 | 280 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1749 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 3241 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 1721 | 0.040 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2016 | 4 | 0.040 |
Why?
|
| Kidney | 1 | 2003 | 1241 | 0.040 |
Why?
|
| Aerosol Propellants | 2 | 2006 | 2 | 0.040 |
Why?
|
| Mice | 2 | 2016 | 11352 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 3990 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 116 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 26 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 38 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 63 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1753 | 0.030 |
Why?
|
| Keratosis | 1 | 2014 | 21 | 0.030 |
Why?
|
| Stroke | 1 | 2004 | 965 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 62 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 2379 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 204 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 2438 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 286 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2015 | 146 | 0.030 |
Why?
|
| Blood Coagulation | 2 | 2005 | 91 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2015 | 321 | 0.030 |
Why?
|
| Zinc Oxide | 1 | 2013 | 3 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 989 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 135 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2013 | 47 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 2013 | 61 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2013 | 156 | 0.030 |
Why?
|
| Laminin | 1 | 2013 | 85 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Muscles | 1 | 2013 | 194 | 0.030 |
Why?
|
| Regeneration | 1 | 2013 | 143 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 106 | 0.030 |
Why?
|
| Rosaniline Dyes | 1 | 2011 | 9 | 0.030 |
Why?
|
| Facial Nerve Injuries | 1 | 2011 | 10 | 0.030 |
Why?
|
| Collagen | 1 | 2013 | 269 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1991 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2001 | 16 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 407 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 158 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2360 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1805 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1621 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 3362 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 37 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1458 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 1219 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 2378 | 0.020 |
Why?
|
| Receptor, Notch3 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 285 | 0.020 |
Why?
|
| Length of Stay | 2 | 2002 | 702 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2007 | 10 | 0.020 |
Why?
|
| Fat Necrosis | 1 | 2007 | 6 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 193 | 0.020 |
Why?
|
| United States | 1 | 2020 | 6672 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2009 | 121 | 0.020 |
Why?
|
| Contrast Media | 1 | 2013 | 1078 | 0.020 |
Why?
|
| Lameness, Animal | 1 | 2007 | 1 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
| Epitopes | 1 | 2008 | 255 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 258 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 372 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 1294 | 0.020 |
Why?
|
| Hindlimb | 1 | 2007 | 89 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 54 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2501 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2001 | 1961 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 860 | 0.020 |
Why?
|
| Port-Wine Stain | 1 | 2005 | 2 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 969 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2005 | 70 | 0.020 |
Why?
|
| Bone Regeneration | 1 | 2005 | 52 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 2005 | 74 | 0.020 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2004 | 8 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 235 | 0.020 |
Why?
|
| Surface Properties | 1 | 2004 | 130 | 0.020 |
Why?
|
| Particle Size | 1 | 2004 | 122 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2004 | 79 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 674 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 2003 | 10 | 0.010 |
Why?
|
| Laser Therapy | 1 | 2005 | 142 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 2003 | 40 | 0.010 |
Why?
|
| Trauma Severity Indices | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2004 | 137 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1565 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 188 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2002 | 33 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2003 | 227 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 2002 | 61 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2001 | 65 | 0.010 |
Why?
|
| Mammography | 1 | 2003 | 463 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2000 | 116 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 894 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 1036 | 0.010 |
Why?
|